-
Mashup Score: 67Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline - 4 month(s) ago
PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast canc
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 64Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline - 4 month(s) ago
PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast canc
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 63Pregnancy After Breast Cancer in Young BRCA Carriers - 4 month(s) ago
This retrospective cohort study assesses the cumulative incidence of pregnancy after cancer and disease-free survival in BRCA carriers diagnosed with invasive breast cancer at age 40 years or younger.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
My last tweet of 2023 to acknowledge @AIRC_it support to our research aiming to improve #BreastCancer care in young women...proud of our small but important contribution in the field & super grateful to all that have participated ! @OncoAlert @JAMA_current https://t.co/baxASj2ISf https://t.co/TazkbNOu5w
-
-
Mashup Score: 22The OncoAlert Newsletter is NOW OUT Click to Register - 5 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22The OncoAlert Newsletter is NOW OUT Click to Register - 5 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 67Fertility Preservation and Post-treatment Pregnancies in - 5 month(s) ago
Clinical Practice Guidelines – Fertility Preservation and Post-treatment Pregnancies in Post-pubertal Cancer Patients
Source: www.esmo.orgCategories: General Medicine News, Hem/OncsTweet-
Yes, for ovarian function preservation should be offered (particularly in #BreastCancer) but it is not an alternative to cryopreservation procedures for patients interested in #fertilitypreservation…I follow this algorithm of @myESMO guidelines #ESHREjc https://t.co/sG9FOLFG5T https://t.co/zqiXJqxsPF https://t.co/cX8En3HiW5
-
-
Mashup Score: 16Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice - Nature Cancer - 6 month(s) ago
In preclinical studies, Hutt, Loi and colleagues find that mice treated with checkpoint blockade have impaired ovarian function and reserve, associated with increased immune infiltrate, raising considerations about fertility implications for female patients.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue - 6 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Beyond #chemotherapy, we should highlight that we lack data on gonadotoxicity risk with the new targeted treatment options and #immunotherapy...we need more research efforts here https://t.co/nF3nl1RPBn #ESHREjc @maclaudiaa @ESHRE #oncofertility @OncoAlert https://t.co/pW8Ff7cMbi https://t.co/nRbmcLtnPg
-
-
Mashup Score: 11
BackgroundOffering ovarian function and/or fertility preservation strategies in premenopausal women with newly diagnosed breast cancer candidates to undergo chemotherapy is standard of care. However, few data are available on uptake and main reasons for refusing these options.MethodsThe PREFER study (NCT02895165) is an observational, prospective study enrolling premenopausal women with early breast cancer, aged between 18 and 45 years, candidates to receive (neo)adjuvant chemotherapy. Primary objective is to collect information on acceptance rates and reasons for refusal of the proposed strategies for ovarian function and/or fertility preservation available in Italy.ResultsAt the study coordinating center, 223 patients were recruited between November 2012 and December 2020. Median age was 38 years (range 24 – 45 years) with 159 patients (71.3%) diagnosed at ≤40 years. Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) was accepted by 58 out of 64 (90.6%)
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52
This cohort study assesses factors associated with chemotherapy-related amenorrhea and evaluates its association with long-term quality of life among premenopausal women with breast cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
Just out in @JCO_ASCO the @ASCO guideline on germline testing in patients with #BreastCancer: congrats to @MarkRobsonMD and colleagues for this important work that will help improving #cancer care 👏👏👏 @OncoAlert @ASCOPost #BRCA #bcsm https://t.co/07JQaDdbmQ